Cerity Partners LLC Has $12.77 Million Stock Holdings in Organon & Co. (NYSE:OGN)

Cerity Partners LLC grew its holdings in Organon & Co. (NYSE:OGNFree Report) by 94.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 667,340 shares of the company’s stock after purchasing an additional 323,308 shares during the period. Cerity Partners LLC owned approximately 0.26% of Organon & Co. worth $12,766,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of OGN. Versant Capital Management Inc raised its stake in Organon & Co. by 200.2% during the second quarter. Versant Capital Management Inc now owns 1,207 shares of the company’s stock worth $25,000 after acquiring an additional 805 shares in the last quarter. Prospera Private Wealth LLC acquired a new position in Organon & Co. during the 3rd quarter worth approximately $25,000. William B. Walkup & Associates Inc. acquired a new position in Organon & Co. during the 2nd quarter worth approximately $31,000. Abich Financial Wealth Management LLC lifted its stake in Organon & Co. by 5,646.3% in the 3rd quarter. Abich Financial Wealth Management LLC now owns 2,356 shares of the company’s stock valued at $45,000 after purchasing an additional 2,315 shares during the last quarter. Finally, Atlas Capital Advisors LLC grew its stake in shares of Organon & Co. by 2,236.5% during the second quarter. Atlas Capital Advisors LLC now owns 2,243 shares of the company’s stock worth $46,000 after buying an additional 2,147 shares during the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Price Performance

Shares of NYSE:OGN opened at $16.17 on Tuesday. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. Organon & Co. has a 52 week low of $10.84 and a 52 week high of $23.10. The firm has a market cap of $4.16 billion, a PE ratio of 3.21, a price-to-earnings-growth ratio of 0.72 and a beta of 0.84. The firm’s fifty day moving average is $17.52 and its 200-day moving average is $19.74.

Organon & Co. (NYSE:OGNGet Free Report) last announced its earnings results on Thursday, October 31st. The company reported $0.87 EPS for the quarter, missing the consensus estimate of $0.90 by ($0.03). The company had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.56 billion. Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The firm’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.78 earnings per share. Sell-side analysts predict that Organon & Co. will post 3.89 earnings per share for the current year.

Organon & Co. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 12th. Shareholders of record on Tuesday, November 12th will be given a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a yield of 6.93%. The ex-dividend date of this dividend is Tuesday, November 12th. Organon & Co.’s dividend payout ratio is presently 22.22%.

Analysts Set New Price Targets

OGN has been the subject of a number of research reports. Evercore ISI upgraded Organon & Co. to a “strong-buy” rating in a research note on Wednesday, September 18th. JPMorgan Chase & Co. lowered Organon & Co. from a “neutral” rating to an “underweight” rating and lifted their price target for the company from $18.00 to $20.00 in a research note on Friday, September 6th.

Check Out Our Latest Stock Analysis on OGN

Organon & Co. Profile

(Free Report)

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.

Further Reading

Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGNFree Report).

Institutional Ownership by Quarter for Organon & Co. (NYSE:OGN)

Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.